Mechanisms of Upadacitinib in IBD Endoscopic Response

Upadacitinib inflammatory bowel disease endoscopic response mechanism

I will search for studies on upadacitinib in IBD, focusing on endoscopic response data and its mechanism of action.

Key Areas of Research

• Upadacitinib and Cytokine Signaling: JAK-STAT pathway, intestinal inflammation

• Clinical Studies: U-ACHIEVE, U-ACCOMPLISH, mucosal healing

• Mechanism of Action: JAK1 inhibitor, relevance in ulcerative colitis and Crohn's disease

Mechanism of Action

Upadacitinib is a selective, reversible JAK1 inhibitor — it preferentially inhibits JAK1 over JAK2, JAK3, and TYK2. This selectivity matters mechanistically: JAK1 pairs with other JAK family members to transduce signaling from cytokines that are central to intestinal inflammation, particularly IL-6, IL-12, IL-23, type I and II interferons (IFN-α/β, IFN-γ), and IL-4/IL-13. By blocking JAK1-dependent STAT phosphorylation, upadacitinib broadly suppresses this cytokine signaling without the cardiovascular and thrombotic risks attributed to less selective pan-JAK inhibitors like tofacitinib.

Transcriptomics Studies

A transcriptomics substudy nested within the CELEST phase 2 trial (Aguilar et al., Inflammatory Bowel Diseases, 2021) gives the clearest mechanistic picture at the mucosal level. In colonic and ileal biopsies from anti-TNF-refractory Crohn's disease patients, upadacitinib significantly reversed overexpression of inflammatory fibroblast signatures and IFN-γ effector cytotoxic T-cell markers specifically in areas that achieved endoscopic remission — not in uninvolved mucosa. This molecular response was distinct from what's seen with anti-TNF therapy, suggesting upadacitinib addresses a partially non-overlapping set of inflammatory pathways, which likely explains its efficacy in biologic-refractory patients.

A complementary transcriptomic analysis by Wang et al. (2022) confirmed that upadacitinib significantly decreased expression of TNF-inadequate-responder upregulated modules — including innate/adaptive immune responses, interferon signaling, and tissue remodeling — in JAK1 responders, with essentially no change in these modules among placebo-treated or JAK1 non-responder patients.

Serum Biomarker Profiling

Serum biomarker profiling from the U-ACHIEVE phase 2b study found that upadacitinib reduced pro-inflammatory mediators associated with immune cell migration, type I/II IFN responses, T-cell responses, and macrophage/dendritic cell activity in a dose-dependent fashion. Endoscopic improvements specifically correlated with reductions in oncostatin M (OSM), a cytokine increasingly recognized as a predictor of biologic non-response.

Clinical Endoscopic Endpoints

• In UC, the phase 2b U-ACHIEVE study (Sandborn et al., Gastroenterology, 2020) showed a clear dose-response for endoscopic improvement at week 8, reaching about 36% with the 45 mg dose versus 2% with placebo.
• The phase 3 U-ACHIEVE and U-ACCOMPLISH induction trials confirmed superior endoscopic improvement, endoscopic remission, and histologic-endoscopic mucosal improvement at week 8 over placebo.
• In Crohn's disease, the phase 3 U-ENDURE maintenance trial (Panaccione et al., 2025) showed endoscopic response rates at week 52 of about 27% with 15 mg and 41% with 30 mg versus 7% with placebo.

The findings indicate that upadacitinib provides significant endoscopic efficacy driven by broad suppression of JAK1-dependent cytokine pathways, particularly impacting the IFN-γ and inflammatory fibroblast compartments that help explain its value in anti-TNF-refractory disease. The key outstanding mechanistic question is which upstream factors determine JAK1 responder vs. non-responder status. These findings come from an initial literature scan and a comprehensive search would surface additional mechanistic and biomarker work.

Cited Sources

13 cited sources (not included in detail)